Cannabis Law Report

OCTOBER 5, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Investors can register for the event here and view the live presentation here. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. For further information about Anebulo, please visit www.anebulo.com.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

NOVEMBER 12, 2021

THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP).

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”. Watch how Supera-CBD works. “We

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? There are many different medical cannabis products. .

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

FloridaMarijuana.net

AUGUST 15, 2018

Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 82

Pharmaceutical Clinical Trials Research and Development Events 82

Canna Law Blog

OCTOBER 5, 2022

However, if this recommendation is actually taken up by the government, legitimate medical marijuana products may be imported into Japan under its existing laws for pharmaceuticals and medical devices. Japan has also had its issues with synthetic cannabinoids because of current government laws and rules (or lack thereof). .

Marijuana 95

Marijuana Seed-To-Sale Clinical Trials Epilepsy 95

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Project CBD

FEBRUARY 28, 2023

sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. 13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e.,

CBD 144

CBD Seed-To-Sale Food Access 144

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Adverse events were mostly mild and resolved spontaneously.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Cannabis Law Report

AUGUST 25, 2021

Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Science also announced a new CTO, Sheldon Borkin , PhD, who joined in September 2021.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

NORML

SEPTEMBER 20, 2019

But at the Vegas event, she brought good news: She announced that other universities would host her research, and she recently applied for a third-party cultivation license from the DEA, the only federal agency that can legally provide cannabis for clinical study in the US. “It needs FDA approval.”

DEA 227

DEA Research and Development Clinical Trials Patients 227

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

SEPTEMBER 3, 2019

(TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its subsidiary MediPharm Labs Australia Pty. Gaining Momentum in Australia: Facility Construction Update.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

JANUARY 18, 2019

Schedule of Events: Tuesday Jan 22nd 4-6:00 pm. CannaTech is the only Medical Cannabis event of its kind with a global focus that offers senior industry leaders, medical and scientific experts, and new ventures the platform to come together, drive innovation, form partnerships and promote knowledge exchange. Welcoming Remarks.

Research and Development 40

Research and Development Clinical Trials Extraction Therapy 40

Green Relief

MAY 13, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

SEPTEMBER 8, 2021

About Epsilon Healthcare Limited Epsilon Healthcare (ASX:EPN) is an ASX listed diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic, and the Medimar Platform. Schedule 1.

Access 97

Access Research and Development Medicine THC 97

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 40

Programs Research and Development Education Treatment 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 52

CBD THC Conditions Medicine 52

Green Relief

MAY 12, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Jonathan is the CEO and founder of Gilgamesh Pharmaceuticals. in/rickdoblin/ [link]. in/dougdrysdale/ [link]. Jonathan Sporn.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

NOVEMBER 24, 2021

The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Cannabis was more frequently portrayed as a pharmaceutical medicine or drug ( n ?=?11) 2016 ; Sznitman et al. years (Atakan 2012 ). 11) rather than a plant product ( n ?=?4).

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 17, 2019

THC is just one of the cannabinoids in the Cannabis sativa L. The other major cannabinoid of particular interest commercially is cannabidiol (CBD). All told, the global legal cannabis industry, including dried cannabis and products containing cannabinoids, was estimated at US $11.9 The sky’s the limit.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. California. The new law went into immediate effect upon the governor’s signature on October 12, 2019. The new law took effect on July 1, 2019. .”

Legislation 59

Legislation Patients Access Banking 59